Nagano Masahiro, Kuroki Syoji, Mizuta Atsushi, Furukawa Masae, Noshiro Mitsuhide, Chijiiwa Kazuo, Tanaka Masao
Department of Surgery and Oncology, Kyushu University School of Medicine, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.
Steroids. 2004 Sep;69(10):701-9. doi: 10.1016/j.steroids.2004.07.004.
Cholesterol 7alpha-hydroxylase (CYP7A1) is regulated by bile acids through the farnesoid X receptor (FXR) mechanism in a negative feedback fashion. However, the fact that CYP7A1 is down-regulated by intraduodenal administration of bile acid, but not by intravenous administration may not be explained only by this mechanism. The aim of this study was to establish a new rat model with reconstructed or simulated enterohepatic circulation to examine if intravenous or portal administration of bile acid can regulate CYP7A1. Under biliary drainage, taurocholate (0 or 6 micromol/h/100g body weight) was administered continuously for 48h into the duodenum (ID-0/ID-6), femoral vein (IV-0/IV-6), or portal vein (IP-0/IP-6) to create a condition in which biliary bile acids were continuously lost, and a similar dose of taurocholate was supplied to the liver simultaneously. CYP7A1 activity and mRNA expression of the ID-0 group were significantly increased compared with the no treatment (NT) group. CYP7A1 activity and mRNA expression of the ID-6 group were suppressed significantly to 41 and 46% of those of the ID-0 group, respectively. In the IV-6 and IP-6 groups, however, enzyme activity and mRNA expression were decreased slightly, but the suppression was not statistically significant. The results suggested that portal as well as intravenous administration of bile acids cannot suppress bile acid synthesis as effectively as intraduodenal administration. It was concluded that an unidentified regulatory factor other than the nuclear receptors may be involved in bile acid synthesis in vivo.
胆固醇7α-羟化酶(CYP7A1)通过法尼醇X受体(FXR)机制受胆汁酸以负反馈方式调节。然而,十二指肠内给予胆汁酸可下调CYP7A1,而静脉内给予则不能,这一事实可能无法仅用该机制来解释。本研究的目的是建立一种重建或模拟肠肝循环的大鼠新模型,以研究静脉或门静脉给予胆汁酸是否能调节CYP7A1。在胆汁引流情况下,将牛磺胆酸盐(0或6微摩尔/小时/100克体重)持续48小时分别注入十二指肠(ID-0/ID-6)、股静脉(IV-0/IV-6)或门静脉(IP-0/IP-6),以造成胆汁酸持续丢失的情况,并同时向肝脏供应相似剂量的牛磺胆酸盐。与未处理(NT)组相比,ID-0组的CYP7A1活性和mRNA表达显著增加。ID-6组的CYP7A1活性和mRNA表达分别显著抑制至ID-0组的41%和46%。然而,在IV-6组和IP-6组中,酶活性和mRNA表达略有下降,但抑制作用无统计学意义。结果表明,门静脉和静脉给予胆汁酸均不能像十二指肠内给予那样有效地抑制胆汁酸合成。得出的结论是,除核受体外,可能有一个未知的调节因子参与体内胆汁酸合成。